Medtronic Secures CE Mark for Sphere-360 PFA Catheter, Launches U.S. Trial

Event summary

  • Medtronic's Sphere-360 PFA catheter received CE Mark approval in Europe on January 23, 2026.
  • First cases in the Horizon 360 IDE pivotal trial completed in the U.S.
  • Sphere-360 is designed for paroxysmal atrial fibrillation treatment with a rotation-free, single-shot pulsed field ablation approach.
  • European study results showed excellent efficacy, safety, and durability, published in the Heart Rhythm Journal in April 2025.

The big picture

Medtronic's Sphere-360 catheter represents a strategic push into next-generation pulsed field ablation technology, competing directly with its own PulseSelect system. The CE Mark approval and U.S. trial launch position Medtronic to dominate the evolving AFib treatment landscape, where single-shot solutions are gaining preference for their efficiency and patient outcomes. The company's commitment to regular innovation in this space could reshape the electrophysiology market.

What we're watching

Regulatory Progress
The pace at which Sphere-360 advances through U.S. regulatory approvals will determine its market entry timing.
Clinical Outcomes
Whether the Horizon 360 trial results match the European study's strong safety and efficacy data.
Market Adoption
How quickly physicians adopt Sphere-360 compared to existing PFA solutions like PulseSelect.